Focused On-demand Library for General transcription factor IIH subunit 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q13889

UPID:

TF2H3_HUMAN

Alternative names:

Basic transcription factor 2 34 kDa subunit; General transcription factor IIH polypeptide 3; TFIIH basal transcription factor complex p34 subunit

Alternative UPACC:

Q13889; B2R819; B4DNZ6; Q7L0G0; Q96AT7

Background:

General transcription factor IIH subunit 3, also known as the 34 kDa subunit, plays a pivotal role in DNA repair and RNA transcription. It is a component of the TFIIH core complex, essential for nucleotide excision repair (NER) and transcription initiation by RNA polymerase II. In NER, it facilitates the opening of DNA around lesions, enabling damaged oligonucleotide excision and replacement. For transcription, it is crucial for promoter opening and escape, with its kinase module CAK phosphorylating RNA polymerase II to initiate transcription.

Therapeutic significance:

Understanding the role of General transcription factor IIH subunit 3 could open doors to potential therapeutic strategies.